Christophe Hirtz

List of Publications by Year
in descending order

67 papers	1,790 citations	304701 22 h-index	315719 38 g-index
70 all docs	70 docs citations	70 times ranked	3218 citing authors

#	Article	IF	Citations
1	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 1-18.	6.1	14
2	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
3	Changes Occurring on the Activity of Salivary Alpha-Amylase Proteoforms in Two Naturalistic Situations Using a Spectrophotometric Assay. Biology, 2021, 10, 227.	2.8	5
4	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. International Journal of Legal Medicine, 2021, 135, 2081-2089.	2.2	7
5	Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection. Immunologic Research, 2021, 69, 255-263.	2.9	5
6	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
7	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. International Journal of Cancer, 2021, 149, 1605-1618.	5.1	8
8	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. Bioanalysis, 2021, 13, 1029-1035.	1.5	6
9	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 2291-2299.	2.9	7
10	Variation of human salivary alpha-amylase proteoforms in three stimulation models. Clinical Oral Investigations, 2020, 24, 475-486.	3.0	7
11	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimerâ€™s disease: Where do we stand?. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 99-113.	6.1	24
12	Cerebrospinal fluid A beta 1â€“40 peptides increase in Alzheimerâ€™s disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
13	Hepcidin and ferritin levels in restless legs syndrome: a caseâ€“control study. Scientific Reports, 2020, 10, 11914.	3.3	21
14	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
15	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. Neuroscience, 2020, 441, 142-160.	2.3	9
16	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimerâ€™s disease and PET amyloid-positive patient identification. Alzheimer's Research and Therapy, 2020, 12, 26.	6.2	138
17	Soluble Intercellular Adhesion Molecule- (sICAM-) 1, Thrombospondin-1, and Vinculin for the Identification of Septic Shock Patients Suffering from an Invasive Fungal Infection. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	2
18	Efficient extraction of intact HSA-AÎ² peptide complexes from sera: Toward albuminome biomarker identification. Talanta, 2020, 216, 121002.	5.5	4

#	Article	IF	Citations
19	Peripheral Blood and Salivary Biomarkers of Bloodâ€“Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Frontiers in Neurology, 2020, 11, 577312.	2.4	36
20	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. Analytical Chemistry, 2019, 91, 15500-15508.	6.5	6
21	SILK studies â€" capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	10.1	37
22	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. Handbook of Behavioral Neuroscience, 2019, 29, 173-190.	0.7	0
23	Biochemical markers of time since death in cerebrospinal fluid: A first step towardsâ€œForensomicsâ€• Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 274-286.	6.1	8
24	Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. BMJ Open, 2019, 9, e025129.	1.9	17
25	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. Methods in Molecular Biology, 2019, 1959, 163-172.	0.9	0
26	The prognostic value of theÂTau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer, 2019, 19, 110.	2.6	20
27	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1086, 110-117.	2.3	6
28	Association between serum hepcidin level and restless legs syndrome. Movement Disorders, 2018, 33, 618-627.	3.9	25
29	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. Bioanalysis, 2018, 10, 35-45.	1.5	12
30	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. Data in Brief, 2018, 18, 1013-1021.	1.0	12
31	Towards a routine application of Top-Down approaches for label-free discovery workflows. Journal of Proteomics, 2018, 175, 12-26.	2.4	17
32	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Topâ€“Down Proteomics: A Pilot Study. Frontiers in Molecular Neuroscience, 2018, 11, 477.	2.9	20
33	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. Bioanalysis, 2018, 10, 1383-1399.	1.5	5
34	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	10.2	140
35	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. Bioanalysis, 2018, 10, 723-735.	1.5	12
36	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 346-358.	6.1	9

#	Article	IF	Citations
37	Alzheimerâ€™s Disease: Advances in Drug Development. Journal of Alzheimer's Disease, 2018, 65, 3-13.	2.6	45
38	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. Clinica Chimica Acta, 2017, 467, 51-58.	1.1	29
39	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 465-469.	1.6	1
40	Quantification of hepcidin-25 in human cerebrospinal fluid using LCâ€“MS/MS. Bioanalysis, 2017, 9, 337-347.	1.5	12
41	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiology of Aging, 2017, 53, 59-66.	3.1	76
42	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. Analytical and Bioanalytical Chemistry, 2017, 409, 2559-2567.	3.7	16
43	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 173-184.	6.1	19
44	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. Bioanalysis, 2017, 9, 427-434.	1.5	14
45	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesthesia, Critical Care & Pain Medicine, 2017, 36, 391-396.	1.4	9
46	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. Journal of Alzheimer's Disease, 2016, 54, 1291-1295.	2.6	16
47	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	3.3	36
48	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2016, 51, 1033-1043.	2.6	104
49	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 759-764.	2.6	23
50	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clinica Chimica Acta, 2016, 454, 33-38.	1.1	19
51	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. Bioanalysis, 2016, 8, 43-53.	1.5	22
52	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. Journal of Proteome Research, 2016, 15, 667-676.	3.7	91
53	Stable Isotope Labeling by Amino acidin Vivo(SILAV): a new method to explore protein metabolism. Rapid Communications in Mass Spectrometry, 2015, 29, 1917-1925.	1.5	10
54	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. Frontiers in Neuroscience, 2015, 9, 302.	2.8	34

#	Article	IF	Citations
55	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?. Bioanalysis, 2015, 7, 2849-2851.	1.5	1
56	Quantitative detection of amyloid-Î² peptides by mass spectrometry: state of the art and clinical applications. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1483-93.	2.3	30
57	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
58	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid Î² peptides in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2014, 52, 649-55.	2.3	8
59	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. EuPA Open Proteomics, 2014, 3, 60-67.	2.5	19
60	Current and future use of â€œdried blood spotâ€•analyses in clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1897-1909.	2.3	102
61	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clinical Chemistry and Laboratory Medicine, 2013, 51, 919-35.	2.3	47
62	From â€œClinical Proteomicsâ€•to â€œClinical Chemistry Proteomicsâ€• considerations using quantitative mass-spectrometry as a model approach. Clinical Chemistry and Laboratory Medicine, 2012, 50, 235-42.	2.3	7
63	Proteins and proteolysis in pre-term and term human milk and possible implications for infant formulae. International Dairy Journal, 2010, 20, 715-723.	3.0	56
64	Use of Reducing/Nonreducing Two-Dimensional Electrophoresis for the Study of Disulfide-Mediated Interactions between Proteins in Raw and Heated Bovine Milk. Journal of Agricultural and Food Chemistry, 2009, 57, 5948-5955.	5.2	54
65	Proteomic Studies of Saliva: A Proposal for a Standardized Handling of Clinical Samples. Clinical Proteomics, 2007, 3, 13-21.	2.1	23
66	Salivary protein profiling in type I diabetes using two-dimensional electrophoresis and mass spectrometry. Clinical Proteomics, 2006, 2, 117-127.	2.1	18
67	MS characterization of multiple forms of alpha-amylase in human saliva. Proteomics, 2005, 5, 4597-4607.	2.2	70